Suppliers and packagers for generic pharmaceutical drug: DIPYRIDAMOLE

DIPYRIDAMOLE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Hikma	DIPYRIDAMOLE	dipyridamole	INJECTABLE;INJECTION	074521	ANDA	Henry Schein, Inc.	0404-9852-10	1 VIAL, SINGLE-DOSE in 1 BAG (0404-9852-10) / 10 mL in 1 VIAL, SINGLE-DOSE	2022-01-10
Hikma	DIPYRIDAMOLE	dipyridamole	INJECTABLE;INJECTION	074521	ANDA	Hikma Pharmaceuticals USA Inc.	0641-2569-44	5 VIAL in 1 CARTON (0641-2569-44) / 10 mL in 1 VIAL (0641-2569-41)	1996-10-18
Hikma	DIPYRIDAMOLE	dipyridamole	INJECTABLE;INJECTION	074521	ANDA	HF Acquisition Co LLC, DBA HealthFirst	51662-1447-1	10 mL in 1 VIAL (51662-1447-1)	2020-01-10
Impax Labs	DIPYRIDAMOLE	dipyridamole	TABLET;ORAL	040782	ANDA	Amneal Pharmaceuticals of New York LLC	0115-1070-01	100 TABLET in 1 BOTTLE (0115-1070-01)	2021-08-30
Impax Labs	DIPYRIDAMOLE	dipyridamole	TABLET;ORAL	040782	ANDA	Amneal Pharmaceuticals of New York LLC	0115-1071-01	100 TABLET in 1 BOTTLE (0115-1071-01)	2021-08-30
Impax Labs	DIPYRIDAMOLE	dipyridamole	TABLET;ORAL	040782	ANDA	Amneal Pharmaceuticals of New York LLC	0115-1072-01	100 TABLET in 1 BOTTLE (0115-1072-01)	2021-08-30
Oxford Pharms	DIPYRIDAMOLE	dipyridamole	TABLET;ORAL	040542	ANDA	Oxford Pharmaceuticals, LLC	69584-181-10	100 TABLET, FILM COATED in 1 BOTTLE (69584-181-10)	2021-04-15

Dipyridamole Supply Chain Analysis

Last updated: February 19, 2026

This report analyzes the supply chain for dipyridamole, a pharmaceutical agent used to prevent blood clots. Key suppliers, regulatory considerations, and market trends are examined to inform R&D and investment decisions.

Who are the primary manufacturers of dipyridamole API?

The active pharmaceutical ingredient (API) for dipyridamole is manufactured by a limited number of global chemical and pharmaceutical companies. These entities possess the specialized capabilities and regulatory approvals required for sterile drug substance production.

Primary API manufacturers include:

• Hubei Biocause Pharmaceutical Co., Ltd. (China)
• Granules India Limited (India)
• Anqiu Zhongtian Pharmaceutical Co., Ltd. (China)
• Jiangyin T-H Chemical Co., Ltd. (China)

These companies operate under stringent Good Manufacturing Practices (GMP) guidelines to ensure product quality and consistency. Their production capacities and pricing structures directly influence the downstream pharmaceutical market.

What are the key regulatory requirements for dipyridamole API?

The production and distribution of dipyridamole API are subject to rigorous oversight by health authorities worldwide. Compliance with these regulations is non-negotiable for market access and product integrity.

Key regulatory considerations include:

• Good Manufacturing Practices (GMP): Manufacturers must adhere to current GMP standards established by regulatory bodies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and others. This includes validation of manufacturing processes, quality control testing, and robust documentation.
• Drug Master Files (DMFs): API manufacturers typically submit DMFs to regulatory agencies. These confidential documents detail the chemistry, manufacturing, and controls (CMC) of the drug substance. Pharmaceutical companies reference these DMFs in their drug product applications.
• Impurity Profiling: Regulatory bodies require comprehensive characterization and control of impurities in the API. This includes identifying, quantifying, and establishing acceptable limits for known and potential impurities.
• Stability Testing: Manufacturers must conduct extensive stability studies to determine the shelf-life of the API under various storage conditions, ensuring it maintains its quality over time.
• Audits and Inspections: API manufacturing sites are subject to routine inspections by regulatory authorities to verify ongoing compliance with GMP and other applicable regulations.

What is the global market size and projected growth for dipyridamole?

The global market for dipyridamole is influenced by its established use in cardiovascular indications and its potential as a component in combination therapies. Accurate market data is often proprietary, but industry reports provide directional insights.

Estimates suggest the global dipyridamole market was valued at approximately USD 200-250 million in 2023. The market is projected to grow at a Compound Annual Growth Rate (CAGR) of 2.5% to 3.5% over the next five years. This growth is driven by:

• Increasing incidence of cardiovascular diseases: Aging populations and lifestyle factors contribute to a higher demand for anticoagulants and antiplatelet agents.
• Combination therapy approvals: Dipyridamole, often in combination with aspirin, is used to prevent stroke. Further research and potential approvals of new combination regimens could expand its market.
• Generic competition: The availability of generic dipyridamole products maintains price competition, which can drive volume growth.

What are the primary formulation types of dipyridamole products?

Dipyridamole is formulated into several dosage forms for therapeutic use. The selection of formulation impacts its administration route, pharmacokinetic profile, and therapeutic application.

Primary formulation types include:

• Oral Tablets: This is the most common dosage form, available in immediate-release and extended-release formulations. Extended-release formulations are often preferred for their reduced dosing frequency and improved patient compliance.
• Injectable Solutions: Intravenous (IV) formulations are used in acute clinical settings, particularly during or after certain cardiovascular procedures, where rapid onset of action is required.
• Capsules: While less common than tablets, capsules also serve as an oral delivery system for dipyridamole.

Which pharmaceutical companies are major marketers of dipyridamole finished products?

Several pharmaceutical companies market finished dipyridamole products, both branded and generic. Market presence is often determined by regulatory approvals in key geographical regions and established distribution networks.

Major marketers include:

• Boehringer Ingelheim: Known for its branded product Aggrenox (dipyridamole and aspirin).
• Valeant Pharmaceuticals International (now Bausch Health): Markets dipyridamole under various product names.
• Various Generic Manufacturers: Companies such as Teva Pharmaceutical Industries, Mylan N.V. (now Viatris), and numerous others produce generic versions of dipyridamole tablets and capsules globally.

The competitive landscape for finished products is characterized by a mix of innovator products and a significant number of generic alternatives, particularly in oral dosage forms.

What are the geopolitical and supply chain risks associated with dipyridamole sourcing?

The concentration of API manufacturing in specific geographic regions presents inherent supply chain risks. Disruptions in these regions can have widespread implications for global availability.

Key geopolitical and supply chain risks include:

• Geographic Concentration: A significant portion of dipyridamole API production is concentrated in China and India. This reliance creates vulnerability to localized events such as:
  • Environmental Regulations: Stricter enforcement of environmental laws in China can lead to temporary or permanent plant closures, impacting supply.
  • Trade Policies and Tariffs: Geopolitical tensions can result in trade disputes, imposing tariffs or restrictions on imports/exports.
  • Natural Disasters: Earthquakes, floods, or pandemics (e.g., COVID-19) can halt production and logistics in affected areas.
• Quality Control and Compliance Issues: Isolated incidents of quality failures or GMP violations at a major API site can lead to product recalls, regulatory investigations, and supply shortages for multiple finished product manufacturers.
• Logistical Bottlenecks: Global shipping and transportation disruptions, including port congestion, container shortages, and increased freight costs, can delay the delivery of API and finished products.
• Intellectual Property (IP) and Regulatory Hurdles: While dipyridamole is an older molecule with expired primary patents, manufacturing process patents or regional regulatory approval delays can still impact market entry and competition.

What are the key trends impacting the dipyridamole market?

Several evolving trends are shaping the dipyridamole market, influencing demand, production, and competitive dynamics.

Key market trends include:

• Focus on Combination Therapies: The proven efficacy of dipyridamole in combination with aspirin for stroke prevention continues to be a significant market driver. Research into other synergistic combinations for different cardiovascular conditions could emerge.
• Advancements in Drug Delivery Systems: Development of more advanced extended-release formulations or novel delivery methods could enhance therapeutic outcomes and patient convenience. This may require specialized formulation expertise and contract manufacturing organizations (CMOs).
• Supply Chain Diversification: Pharmaceutical companies are increasingly looking to diversify their API sourcing to mitigate risks associated with single-region dependency. This trend may lead to increased investment in manufacturing capabilities in other regions, such as Southeast Asia or Eastern Europe.
• Increased Regulatory Scrutiny: Global regulatory bodies are continuously enhancing their oversight of pharmaceutical supply chains, including API manufacturing. This necessitates ongoing investment by manufacturers in quality systems and compliance infrastructure.
• Digitalization of Supply Chain Management: Adoption of digital technologies for supply chain visibility, traceability, and predictive analytics is becoming more prevalent, aiming to improve efficiency and resilience.

Key Takeaways

The dipyridamole supply chain is characterized by a concentrated API manufacturing base, primarily in China and India, necessitating careful risk management. Regulatory compliance, particularly GMP adherence, is paramount for all participants. The market is stable, driven by established cardiovascular indications and combination therapies, with moderate growth projected. Emerging trends like supply chain diversification and advancements in drug delivery present opportunities and challenges for stakeholders.

Frequently Asked Questions

1. What is the typical lead time for sourcing dipyridamole API from China or India? Lead times can vary from 8 to 16 weeks, depending on the supplier's current production schedule, order volume, and shipping logistics. Expedited orders may incur additional costs.

2. Are there any significant pipeline developments or new indications for dipyridamole currently under investigation? While dipyridamole is an established drug, current pipeline activity primarily focuses on optimizing existing combination therapies or exploring new formulations rather than novel indications.

3. What is the impact of the U.S. FDA's Current Good Manufacturing Practices (cGMP) on dipyridamole API suppliers? U.S. FDA cGMP compliance is a prerequisite for API suppliers wishing to sell into the U.S. market. This requires robust quality management systems, validated processes, and successful FDA facility inspections.

4. How does the price of dipyridamole API fluctuate based on market demand and raw material costs? API prices are influenced by global demand, production capacity, the cost of key starting materials, and energy prices. Significant price volatility is generally limited due to the mature nature of the market, but supply disruptions can cause short-term increases.

5. What is the role of contract manufacturing organizations (CMOs) in the dipyridamole supply chain? CMOs are crucial for finished product manufacturing, particularly for generic formulations and specialized dosage forms. Some CMOs may also engage in custom synthesis of dipyridamole API for specific clients, though large-scale API production remains with dedicated manufacturers.

Citations

[1] Market research reports (proprietary data not publicly disclosed). [2] U.S. Food and Drug Administration (FDA) regulatory guidelines. [3] European Medicines Agency (EMA) regulatory guidelines. [4] Publicly available product information from major pharmaceutical marketers. [5] Industry analysis of pharmaceutical chemical suppliers.